| Predicted Trait | |
| Reported Trait | Coronary artery disease |
| Mapped Trait(s) | coronary artery disease (EFO_0001645) |
| Score Construction | |
| PGS Name | PRS70_CAD |
| Development Method | |
| Name | Genome-wide significant variants |
| Parameters | p < 5e-8 |
| Variants | |
| Original Genome Build | GRCh37 |
| Number of Variants | 70 |
| Effect Weight Type | log(HR) |
| PGS Source | |
| PGS Catalog Publication (PGP) ID | PGP000114 |
| Citation (link to publication) | Pechlivanis S et al. BMC Med Genet (2020) |
| Ancestry Distribution | |
| Source of Variant Associations (GWAS) | |
| PGS Evaluation | European: 100% 8 Sample Sets |
| Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
|---|---|---|---|
GWAS Catalog: GCST003116 Europe PMC: 26343387 |
11,323 individuals | East Asian | 41 cohorts
|
GWAS Catalog: GCST003116 Europe PMC: 26343387 |
141,217 individuals | European | 41 cohorts
|
GWAS Catalog: GCST000998 Europe PMC: 21378990 |
86,995 individuals | European | 12 cohorts
|
Europe PMC: 23202125 |
[
|
European, South Asian, NR | 40 cohorts
|
Europe PMC: 28209224 |
[
|
European | 24 cohorts
|
GWAS Catalog: GCST003116 Europe PMC: 26343387 |
3,139 individuals | African American or Afro-Caribbean | 41 cohorts
|
GWAS Catalog: GCST003116 Europe PMC: 26343387 |
2,268 individuals | Greater Middle Eastern (Middle Eastern, North African or Persian) | 40 cohorts
|
GWAS Catalog: GCST003116 Europe PMC: 26343387 |
4,095 individuals | Hispanic or Latin American | 41 cohorts
|
GWAS Catalog: GCST003116 Europe PMC: 26343387 |
25,557 individuals | South Asian | 41 cohorts
|
|
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|
| PPM000996 | PSS000508| European Ancestry| 3,748 individuals |
PGP000114 | Pechlivanis S et al. BMC Med Genet (2020) |
Reported Trait: Coronary artery calcification | OR: 1.19 [1.1, 1.29] | — | — | age, sex, cardiovascular risk factors (systolic blood pressure, antihypertensive medication, smoking, LDL-cholestrol, HDL-cholesterol, lipid lowering medication, BMI and diabetes). | — |
| PPM000995 | PSS000505| European Ancestry| 4,041 individuals |
PGP000114 | Pechlivanis S et al. BMC Med Genet (2020) |
Reported Trait: Coronary artery calcification | OR: 1.18 [1.1, 1.27] | — | — | age, sex, cardiovascular risk factors (systolic blood pressure, antihypertensive medication, smoking, LDL-cholestrol, HDL-cholesterol, lipid lowering medication, BMI and diabetes). | — |
| PPM000993 | PSS000509| European Ancestry| 2,560 individuals |
PGP000114 | Pechlivanis S et al. BMC Med Genet (2020) |
Reported Trait: Incident Coronary Heart Disease in indiviuals with coronary artery calcification > 0 | HR: 1.21 [1.08, 1.36] | — | — | age, sex, cardiovascular risk factors (systolic blood pressure, antihypertensive medication, smoking, LDL-cholestrol, HDL-cholesterol, lipid lowering medication, BMI and diabetes). | — |
| PPM000992 | PSS000510| European Ancestry| 1,765 individuals |
PGP000114 | Pechlivanis S et al. BMC Med Genet (2020) |
Reported Trait: Incident Coronary Heart Disease in males | HR: 1.23 [1.07, 1.41] | — | — | age, cardiovascular risk factors (systolic blood pressure, antihypertensive medication, smoking, LDL-cholestrol, HDL-cholesterol, lipid lowering medication, BMI and diabetes) and coronary artery calcification. | — |
| PPM000991 | PSS000506| European Ancestry| 1,919 individuals |
PGP000114 | Pechlivanis S et al. BMC Med Genet (2020) |
Reported Trait: Incident Coronary Heart Disease in males | HR: 1.25 [1.1, 1.42] | — | — | age | — |
| PPM000990 | PSS000507| European Ancestry| 3,748 individuals |
PGP000114 | Pechlivanis S et al. BMC Med Genet (2020) |
Reported Trait: Incident Coronary Heart Disease | HR: 1.18 [1.06, 1.31] | — | — | age, sex, cardiovascular risk factors (systolic blood pressure, antihypertensive medication, smoking, LDL-cholestrol, HDL-cholesterol, lipid lowering medication, BMI and diabetes) and coronary artery calcification. | — |
| PPM000989 | PSS000504| European Ancestry| 4,041 individuals |
PGP000114 | Pechlivanis S et al. BMC Med Genet (2020) |
Reported Trait: Incident Coronary Heart Disease | HR: 1.18 [1.06, 1.31] | — | — | age, sex | — |
| PPM000994 | PSS000511| European Ancestry| 1,426 individuals |
PGP000114 | Pechlivanis S et al. BMC Med Genet (2020) |
Reported Trait: Incident Coronary Heart Disease in males with coronary artery calcification > 0 | HR: 1.26 [1.09, 1.46] | — | — | age, cardiovascular risk factors (systolic blood pressure, antihypertensive medication, smoking, LDL-cholestrol, HDL-cholesterol, lipid lowering medication, BMI and diabetes). | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS000504 | Participants with no prior Coronary Heart Disease (CHD) at the time of enrollment were included within the present study. Incidental CHD was the primary end-points of the study. CHD was defined as fatal and non-fatal myocardial infarction, stroke and coronary death. | Median = 11.6 years Sd = 3.7 years |
[ ,
47.5 % Male samples |
Mean = 58.9 years Sd = 7.6 years |
European | — | HNR | — |
| PSS000505 | — | — | [
|
— | European | — | HNR | — |
| PSS000506 | Male participants with no prior Coronary Heart Disease (CHD) at the time of enrollment were included within the present study. Incidental CHD was the primary end-points of the study. CHD was defined as fatal and non-fatal myocardial infarction, stroke and coronary death. | — | [ ,
100.0 % Male samples |
— | European | — | HNR | — |
| PSS000507 | Participants with no prior Coronary Heart Disease (CHD) at the time of enrollment were included within the present study. Incidental CHD was the primary end-points of the study. CHD was defined as fatal and non-fatal myocardial infarction, stroke and coronary death. Cardiovascular risk factor data required included smoking status, current use of medication, body mass index, levels of serum triglycerides, low densitity lipoprotein-cholesterol and high densitity lipoprotein-cholesterol and diabetes defined as either of 4 criteria (1) participants reported a history of clinically diagnosed diabetes, (2) participants took glucose-lowering medications, (3) participants had fasting glucose levels of greater than 125mg/dL or (4) participants had non-fasting glucose levels of 200mg/dL or greater. | — | [
|
— | European | — | HNR | — |
| PSS000508 | — | — | [
|
— | European | — | HNR | — |
| PSS000509 | Participants with no prior Coronary Heart Disease (CHD) at the time of enrollment with coronary artery calcification>0 were included. Incidental CHD was the primary end-points of the study. CHD was defined as fatal and non-fatal myocardial infarction, stroke and coronary death. Cardiovascular risk factor data required included smoking status, current use of medication, body mass index, levels of serum triglycerides, low densitity lipoprotein-cholesterol and high densitity lipoprotein-cholesterol and diabetes defined as either of 4 criteria (1) participants reported a history of clinically diagnosed diabetes, (2) participants took glucose-lowering medications, (3) participants had fasting glucose levels of greater than 125mg/dL or (4) participants had non-fasting glucose levels of 200mg/dL or greater. | — | [
|
— | European | — | HNR | — |
| PSS000510 | Male participants with no prior Coronary Heart Disease (CHD) at the time of enrollment were included within the present study. Incidental CHD was the primary end-points of the study. CHD was defined as fatal and non-fatal myocardial infarction, stroke and coronary death. Cardiovascular risk factor data required included smoking status, current use of medication, body mass index, levels of serum triglycerides, low densitity lipoprotein-cholesterol and high densitity lipoprotein-cholesterol and diabetes defined as either of 4 criteria (1) participants reported a history of clinically diagnosed diabetes, (2) participants took glucose-lowering medications, (3) participants had fasting glucose levels of greater than 125mg/dL or (4) participants had non-fasting glucose levels of 200mg/dL or greater. | — | [ ,
100.0 % Male samples |
— | European | — | HNR | — |
| PSS000511 | Male participants with no prior Coronary Heart Disease (CHD) at the time of enrollment with coronary artery calcification>0 were included. Incidental CHD was the primary end-points of the study. CHD was defined as fatal and non-fatal myocardial infarction, stroke and coronary death. Cardiovascular risk factor data required included smoking status, current use of medication, body mass index, levels of serum triglycerides, low densitity lipoprotein-cholesterol and high densitity lipoprotein-cholesterol and diabetes defined as either of 4 criteria (1) participants reported a history of clinically diagnosed diabetes, (2) participants took glucose-lowering medications, (3) participants had fasting glucose levels of greater than 125mg/dL or (4) participants had non-fasting glucose levels of 200mg/dL or greater. | — | [ ,
100.0 % Male samples |
— | European | — | HNR | — |